RA Capital Management’s Olema Pharmaceuticals OLMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-2,600,000
Closed -$38.8M 89
2026
Q1
$38.8M Hold
2,600,000
0.41% 40
2025
Q4
$65M Buy
+2,600,000
New +$46.3M 0.67% 31
2022
Q3
Sell
-233,793
Closed -$952K 93
2022
Q2
$952K Sell
233,793
-270,712
-54% -$859K 0.03% 85
2022
Q1
$2.15M Sell
504,505
-1,645,899
-77% -$9.07M 0.05% 94
2021
Q4
$20.1M Hold
2,150,404
0.35% 60
2021
Q3
$59.3M Hold
2,150,404
0.82% 37
2021
Q2
$60.2M Hold
2,150,404
0.97% 29
2021
Q1
$71.3M Hold
2,150,404
1.08% 30
2020
Q4
$103M Buy
+2,150,404
New +$101M 1.45% 21

Other funds holding OLMA

RA Capital Management's OLMA Position: Q2 2026 in Review

RA Capital Management sold out of Olema Pharmaceuticals (OLMA) in Q2 2026, closing a stake of 2,600,000 shares — an estimated $38.8M sold.

RA Capital Management first reported a position in OLMA in Q4 2020 and held it in 9 quarters. The position peaked at $103M in Q4 2020. 185 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • RA Capital Management reported no remaining Olema Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • RA Capital Management sold 2,600,000 Olema Pharmaceuticals shares in Q2 2026, an estimated $38.8M.
  • RA Capital Management first reported a position in Olema Pharmaceuticals in Q4 2020 and held it in 9 quarters.
  • RA Capital Management's Olema Pharmaceuticals position peaked at $103M in Q4 2020.
  • 185 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.